Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease

Neurobiology of Aging

Volumn 28, Issue 8, 2007, Pages 1239-1247

  Wu, Ying Hui ^a   Zhou, Jiang Ning ^b   Van Heerikhuize, Joop ^a   Jockers, Ralf ^c,d,e,f   Swaab, Dick F ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c INSTITUT COCHIN   (France)

^d INSERM   (France)

^e CNRS   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Aging; Alzheimer's disease; AVP; Immunocytochemistry; Melatonin receptor; MT1; Suprachiasmatic nucleus; VIP

Indexed keywords

MELATONIN 1 RECEPTOR; NEUROPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOPRESSIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CELL DENSITY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; MALE; NERVE CELL; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPRACHIASMATIC NUCLEUS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; NEURONS; POSTMORTEM CHANGES; RECEPTOR, MELATONIN, MT1; STATISTICS, NONPARAMETRIC; SUPRACHIASMATIC NUCLEUS; VASOACTIVE INTESTINAL PEPTIDE; VASOPRESSINS;

EID: 34249291586     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.06.002     Document Type: Article

References (43)

1. Adams J.C. Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J Histochem Cytochem 40 10 (1992) 1457-1463
2. Arendt J., Skene D.J., Middleton B., Lockley S.W., and Deacon S. Efficacy of melatonin treatment in jet lag, shift work, and blindness. J Biol Rhythms 12 6 (1997) 604-617
3. Benloucif S., Masana M.I., and Dubocovich M.L. Responsiveness to melatonin and its receptor expression in the aging circadian clock of mice. Am J Physiol 273 6 Pt 2 (1997) R1855-R1860
4. Braak H., and Braak E. Neuropathological stages of Alzheimer-related changes. Acta Neuropathol (Berl) 82 4 (1991) 239-259
5. Brydon L., Roka F., Petit L., de Coppet P., Tissot M., Barrett P., et al. Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. Mol Endocrinol 13 12 (1999) 2025-2038
6. Buijs R.M., and Kalsbeek A. Hypothalamic integration of central and peripheral clocks. Nat Rev Neurosci 2 7 (2001) 521-526
7. Dubocovich M.L., Yun K., Al-Ghoul W.M., Benloucif S., and Masana M.I. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. Faseb J 12 12 (1998) 1211-1220
8. Gauer F., Masson-Pevet M., and Pevet P. Melatonin receptor density is regulated in rat pars tuberalis and suprachiasmatic nuclei by melatonin itself. Brain Res 602 1 (1993) 153-156
9. Gauer F., Masson-Pevet M., Stehle J., and Pevet P. Daily variations in melatonin receptor density of rat pars tuberalis and suprachiasmatic nuclei are distinctly regulated. Brain Res 641 1 (1994) 92-98
10. Hofman M.A., and Swaab D.F. Alterations in circadian rhythmicity of the vasopressin-producing neurons of the human suprachiasmatic nucleus (SCN) with aging. Brain Res 651 1-2 (1994) 134-142
11. Hofman M.A., and Swaab D.F. Influence of aging on the seasonal rhythm of the vasopressin-expressing neurons in the human suprachiasmatic nucleus. Neurobiol Aging 16 6 (1995) 965-971
12. Hunt A.E., Al-Ghoul W.M., Gillette M.U., and Dubocovich M.L. Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol 280 1 (2001) C110-C118
13. Liu C., Weaver D.R., Jin X., Shearman L.P., Pieschl R.L., Gribkoff V.K., et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 19 1 (1997) 91-102
14. Liu R.Y., Zhou J.N., Hoogendijk W.J., van Heerikhuize J., Kamphorst W., Unmehopa U.A., et al. Decreased vasopressin gene expression in the biological clock of Alzheimer disease patients with and without depression. J Neuropathol Exp Neurol 59 4 (2000) 314-322
15. Lovell B.B., Ancoli-Israel S., and Gevirtz R. Effect of bright light treatment on agitated behavior in institutionalized elderly subjects. Psychiatry Res 57 1 (1995) 7-12
16. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 7 (1984) 939-944
17. Mirmiran M., Swaab D.F., Kok J.H., Hofman M.A., Witting W., and Van Gool W.A. Circadian rhythms and the suprachiasmatic nucleus in perinatal development, aging and Alzheimer's disease. Prog Brain Res 93 (1992) 151-162 [discussion 62-3]
18. Okawa M., Mishima K., Hishikawa Y., Hozumi S., Hori H., and Takahashi K. Circadian rhythm disorders in sleep-waking and body temperature in elderly patients with dementia and their treatment. Sleep 14 6 (1991) 478-485
19. Pollak C.P., and Perlick D. Sleep problems and institutionalization of the elderly. J Geriatr Psychiatry Neurol 4 4 (1991) 204-210
20. Reppert S.M., Weaver D.R., Rivkees S.A., and Stopa E.G. Putative melatonin receptors in a human biological clock. Science 242 4875 (1988) 78-81
21. Reppert S.M., Weaver D.R., and Godson C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol Sci 17 3 (1996) 100-102
22. Romijn H.J., van Uum J.F., Emmering J., Goncharuk V., and Buijs R.M. Colocalization of VIP with AVP in neurons of the human paraventricular, supraoptic and suprachiasmatic nucleus. Brain Res 832 1-2 (1999) 47-53
23. Satlin A., Volicer L., Ross V., Herz L., and Campbell S. Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer's disease. Am J Psychiatry 149 8 (1992) 1028-1032
24. Savaskan E., Olivieri G., Meier F., Brydon L., Jockers R., Ravid R., et al. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J Pineal Res 32 1 (2002) 59-62
25. Savaskan E., Ayoub M.A., Ravid R., Angeloni D., Fraschini F., Meier F., et al. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J Pineal Res 38 1 (2005) 10-16
26. Schuster C., Gauer F., Malan A., Recio J., Pevet P., and Masson-Pevet M. The circadian clock, light/dark cycle and melatonin are differentially involved in the expression of daily and photoperiodic variations in mt(1) melatonin receptors in the Siberian and Syrian hamsters. Neuroendocrinology 74 1 (2001) 55-68
27. Serfaty M., Kennell-Webb S., Warner J., Blizard R., and Raven P. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry 17 12 (2002) 1120-1127
28. Singer C., Tractenberg R.E., Kaye J., Schafer K., Gamst A., Grundman M., et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 26 7 (2003) 893-901
29. Skene D.J., and Swaab D.F. Melatonin rhythmicity: effect of age and Alzheimer's disease. Exp Gerontol 38 1-2 (2003) 199-206
30. Swaab D.F., Fliers E., and Partiman T.S. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res 342 1 (1985) 37-44
31. Swaab D.F. The human hypothalamus: basic and clinical aspects. In: Aminoff M.J., and Boller F. (Eds). Handbook of clinical neurology vol. 1 (2003), Elsevier, Amsterdam 3rd series
32. Thomas L., Purvis C.C., Drew J.E., Abramovich D.R., and Williams L.M. Melatonin receptors in human fetal brain: 2-[(125)I]iodomelatonin binding and MT1 gene expression. J Pineal Res 33 4 (2002) 218-224
33. Van de Nes J.A., Kamphorst W., Ravid R., and Swaab D.F. Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: amorphic plaques and cytoskeletal changes occur independently. Acta Neuropathol (Berl) 96 2 (1998) 129-138
34. Van der Sluis P.J., Pool C.W., and Sluiter A.A. Immunochemical detection of peptides and proteins on press-blots after direct tissue gel isoelectric focusing. Electrophoresis 9 10 (1988) 654-661
35. Van Someren E.J., Hagebeuk E.E., Lijzenga C., Scheltens P., de Rooij S.E., Jonker C., et al. Circadian rest-activity rhythm disturbances in Alzheimer's disease. Biol Psychiatry 40 4 (1996) 259-270
36. Van Someren E.J., Kessler A., Mirmiran M., and Swaab D.F. Indirect bright light improves circadian rest--activity rhythm disturbances in demented patients. Biol Psychiatry 41 9 (1997) 955-963
37. Weaver D.R., and Reppert S.M. The Mel1a melatonin receptor gene is expressed in human suprachiasmatic nuclei. Neuroreport 8 1 (1996) 109-112
38. Whealin J.M., Burwell R.D., and Gallagher M. The effects of aging on diurnal water intake and melatonin binding in the suprachiasmatic nucleus. Neurosci Lett 154 1-2 (1993) 149-152
39. Wu Y.H., Feenstra M.G., Zhou J.N., Liu R.Y., Torano J.S., Van Kan H.J., et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 88 12 (2003) 5898-5906
40. Wu Y.H., and Swaab D.F. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res 38 3 (2005) 145-152
41. Zhou J.N., Hofman M.A., and Swaab D.F. VIP neurons in the human SCN in relation to sex, age, and Alzheimer's disease. Neurobiol Aging 16 4 (1995) 571-576
42. Zhou J.N., Liu R.Y., Kamphorst W., Hofman M.A., and Swaab D.F. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 35 2 (2003) 125-130
43. Zisapel N. The use of melatonin for the treatment of insomnia. Biol Signals Recept 8 1-2 (1999) 84-89